|
1
|
Scherpereel A, Astoul P, Baas P, Berghmans
T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin
C, Hillerdal G, et al: Guidelines of the European respiratory
society and the European society of thoracic surgeons for the
management of malignant pleural mesothelioma. Eur Respir J.
35:479–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sekido Y: Molecular pathogenesis of
malignant mesothelioma. Carcinogenesis. 34:1413–1419. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Husain AN, Colby TV, Ordóñez NG, Allen TC,
Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S,
et al: Guidelines for pathologic diagnosis of malignant
mesothelioma 2017 update of the consensus statement from the
international mesothelioma interest group. Arch Pathol Lab Med.
142:89–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alì G, Bruno R and Fontanini G: The
pathological and molecular diagnosis of malignant pleural
mesothelioma: A literature review. J Thorac Dis. 10 (Suppl
2):S276–S284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galateau-Salle F, Churg A, Roggli V and
Travis WD; World Health Organization Committee for Tumors of the
Pleura, : The 2015 World Health Organization Classification of
Tumors of the Pleura: Advances since the 2004 classification. J
Thorac Oncol. 11:142–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hjerpe A, Ascoli V, Bedrossian C, Boon M,
Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A, et
al: Guidelines for cytopathologic diagnosis of epithelioid and
mixed type malignant mesothelioma. Complementary statement from the
International Mesothelioma Interest Group, also endorsed by the
International Academy of Cytology and the Papanicolaou Society of
Cytopathology. Cytojournal. 12:262015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bruno R, Alì G and Fontanini G: Molecular
markers and new diagnostic methods to differentiate malignant from
benign mesothelial pleural proliferations: A literature review. J
Thorac Dis. 10 (Suppl 2):S342–S352. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Churg A, Sheffield BS and Galateau-Salle
F: New markers for separating benign from malignant mesothelial
proliferations: Are we there yet? Arch Pathol Lab Med. 140:318–321.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ladanyi M: Implications of P16/CDKN2A
deletion in pleural mesotheliomas. Lung Cancer. 49 (Suppl
1):S95–S98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Illei PB, Ladanyi M, Rusch VW and Zakowski
MF: The use of CDKN2A deletion as a diagnostic marker for malignant
mesothelioma in body cavity effusions. Cancer. 99:51–56. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dacic S, Kothmaier H, Land S, Shuai Y,
Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag
F, et al: Prognostic significance of p16/cdkn2a loss in pleural
malignant mesotheliomas. Virchows Arch. 453:627–635. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung CT, Santos GD, Hwang DM, Ludkovski
O, Pintilie M, Squire JA and Tsao MS: FISH assay development for
the detection of p16/CDKN2A deletion in malignant pleural
mesothelioma. J Clin Pathol. 63:630–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheffield BS, Hwang HC, Lee AF, Thompson
K, Rodriguez S, Tse CH, Gown AM and Churg A: BAP1
immunohistochemistry and p16 FISH to separate benign from malignant
mesothelial proliferations. Am J Surg Pathol. 39:977–982. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bruno R, Alì G, Giannini R, Proietti A,
Lucchi M, Chella A, Melfi F, Mussi A and Fontanini G: Malignant
pleural mesothelioma and mesothelial hyperplasia: A new molecular
tool for the differential diagnosis. Oncotarget. 8:2758–2770. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to the 2015 World Health
Organization Classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cigognetti M, Lonardi S, Fisogni S,
Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G,
Murer B, et al: BAP1 (BRCA1-associated protein 1) is a highly
specific marker for differentiating mesothelioma from reactive
mesothelial proliferations. Mod Pathol. 28:1043–1057. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McGregor SM, Dunning R, Hyjek E,
Vigneswaran W, Husain AN and Krausz T: BAP1 facilitates diagnostic
objectivity, classification, and prognostication in malignant
pleural mesothelioma. Hum Pathol. 46:1670–1678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McGregor SM, McElherne J, Minor A,
Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C
and Krausz T: BAP1 immunohistochemistry has limited prognostic
utility as a complement of CDKN2A (p16) fluorescence in situ
hybridization in malignant pleural mesothelioma. Hum Pathol.
60:86–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiosea S, Krasinskas A, Cagle PT,
Mitchell KA, Zander DS and Dacic S: Diagnostic importance of 9p21
homozygous deletion in malignant mesotheliomas. Mod Pathol.
21:742–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Monaco SE, Shuai Y, Bansal M, Krasinskas
AM and Dacic S: The diagnostic utility of p16 FISH and GLUT-1
immunohistochemical analysis in mesothelial proliferations. Am J
Clin Pathol. 135:619–627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Churg A, Colby TV, Cagle P, Corson J,
Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V and Travis WD: The
separation of benign and malignant mesothelial proliferations. Am J
Surg Pathol. 24:1183–1200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Husain AN: Mesothelial proliferations:
Useful marker is not the same as a diagnostic one. Am J Clin
Pathol. 141:152–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nasu M, Emi M, Pastorino S, Tanji M,
Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, et al:
High Incidence of Somatic BAP1 alterations in sporadic malignant
mesothelioma. J Thorac Oncol. 10:565–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang HC, Sheffield BS, Rodriguez S,
Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1
immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of
malignant mesothelioma in effusion cytology specimens. Am J Surg
Pathol. 40:120–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsang HF, Xue VW, Koh SP, Chiu YM, Ng LP
and Wong SC: NanoString, a novel digital color-coded barcode
technology: Current and future applications in molecular
diagnostics. Expert Rev Mol Diagn. 17:95–103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Linton A, Cheng YY, Griggs K, Schedlich L,
Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC,
Klebe S, et al: An RNAi-based screen reveals PLK1, CDK1 and NDC80
as potential therapeutic targets in malignant pleural mesothelioma.
Br J Cancer. 110:510–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kato T, Lee D, Wu L, Patel P, Young AJ,
Wada H, Hu HP, Ujiie H, Kaji M, Kano S, et al: SORORIN and PLK1 as
potential therapeutic targets in malignant pleural mesothelioma.
Int J Oncol. 49:2411–2420. 2016. View Article : Google Scholar : PubMed/NCBI
|
